Eli Lilly's Weight Loss Portfolio Generates $10 Billion in Quarterly Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Market Leadership: Eli Lilly's leadership in the weight loss drug market has resulted in its weight loss portfolio generating $10 billion in revenue in the latest quarter, driving overall revenue growth in double digits and demonstrating strong performance in a high-demand sector.
- Product Innovation Potential: Eli Lilly plans to launch the oral weight loss drug orforglipron, which is expected to further enhance market share due to its convenience and lower manufacturing costs compared to injectables, potentially attracting more patients.
- Sustained Demand Growth: High demand for Lilly's injectable drugs has led to shortages, prompting the company to expand its manufacturing capacity to meet the growing market needs, with analysts predicting the obesity drug market will approach $100 billion by 2030.
- Competitive Advantage: Although Novo Nordisk's weight loss pill has been approved, Lilly's orforglipron, which does not require dietary restrictions, may be easier for patients to incorporate into their daily routines, potentially capturing a larger market share and further solidifying its market position.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1032.970
Low
950.00
Averages
1192
High
1500
Current: 1032.970
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
